Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: SOP for Conducting Forced Degradation Study – V 2.0

Posted on By

Analytical Method Development: SOP for Conducting Forced Degradation Study – V 2.0

Standard Operating Procedure for Performing Forced Degradation Studies in Analytical Method Development


Department Analytical Method Development
SOP No. SOP/AMD/186/2025
Supersedes SOP/AMD/186/2022
Page No. Page 1 of 14
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

To establish a standard procedure for performing forced degradation studies on active pharmaceutical ingredients (APIs) and finished products to demonstrate the specificity and stability-indicating nature

of analytical methods. The studies help in identifying potential degradation pathways and degradation products.

2. Scope

This SOP applies to all APIs and drug products under development or stability evaluation in the Analytical Method Development (AMD) department. It includes acidic, basic, oxidative, thermal, and photolytic degradation conditions.

3. Responsibilities

  • Analytical Scientist: Designs degradation study protocols and monitors study progress.
  • Lab Analyst: Executes degradation experiments, samples, and analyzes data.
  • QA Officer: Reviews degradation profiles and ensures proper documentation.
  • Head – AMD: Approves final degradation reports and ensures regulatory compliance.
See also  Analytical Method Development: Pathogen Detection Method Development - V 2.0

4. Accountability

The Head of AMD is accountable for ensuring the forced degradation studies are conducted in accordance with ICH guidelines and support the stability-indicating nature of the analytical method.

5. Procedure

5.1 Preparation of Degradation Study Plan

  1. Draft a degradation protocol that includes:
    • List of degradation conditions to be evaluated
    • Concentration of stress agents
    • Sampling time points
    • Analytical method and detection wavelength
  2. Review and approve the plan prior to initiation.

5.2 Stress Conditions and Treatment

  1. Acid Hydrolysis: Use 0.1N HCl; expose sample for 1–3 hours at 60°C.
  2. Base Hydrolysis: Use 0.1N NaOH; treat for 1–3 hours at 60°C.
  3. Oxidation: Use 3% H₂O₂; incubate at room temperature for 1–6 hours.
  4. Thermal Stress: Expose solid or solution at 80°C for 24–48 hours in a hot air oven.
  5. Photolytic Degradation: Expose to UV and visible light (1.2 million lux hours and 200 Wh/m² UV).
See also  Analytical Method Development: Development of Drug Release Profile - V 2.0

5.3 Sample Neutralization and Dilution

  1. Neutralize acid/base hydrolyzed samples using appropriate neutralizer (NaOH for acid, HCl for base) prior to analysis.
  2. Filter samples using 0.45 µm PVDF filter if required.
  3. Dilute samples to required concentration with mobile phase or diluent.

5.4 Analysis and Data Interpretation

  1. Analyze each sample using validated HPLC/UPLC/UV method.
  2. Record retention time, area, purity, and any new degradation peaks.
  3. Compare chromatograms of stressed vs. unstressed samples.
  4. Determine percentage degradation; should ideally be between 5%–20% for method suitability.
  5. Summarize in Annexure-1: Forced Degradation Summary Report.

5.5 Documentation and Reporting

  1. Prepare degradation study report with:
    • Study design and conditions
    • Chromatograms and data tables
    • Conclusion on method specificity and peak purity
  2. Review by QA and approval by Head – AMD.

6. Abbreviations

  • API: Active Pharmaceutical Ingredient
  • HPLC: High-Performance Liquid Chromatography
  • UV: Ultraviolet
  • SOP: Standard Operating Procedure
  • ICH: International Council for Harmonisation

See also  Analytical Method Development: Morphology Assessment SOP - V 2.0

7. Documents

  1. Forced Degradation Summary Report – Annexure-1

8. References

  • ICH Q1A(R2) – Stability Testing of New Drug Substances and Products
  • ICH Q2(R2) – Validation of Analytical Procedures
  • FDA Guidance for Industry – Analytical Procedures and Methods Validation

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Forced Degradation Summary Report

Stress Condition Reagent/Temp/Time % Degradation New Peaks Observed Remarks
Acid Hydrolysis 0.1N HCl, 60°C, 2 hrs 12.6% Yes Complies
Base Hydrolysis 0.1N NaOH, 60°C, 2 hrs 9.8% No Complies
Oxidation 3% H₂O₂, RT, 4 hrs 15.2% Yes Complies
Thermal 80°C, 48 hrs 6.7% No Complies
Photolytic UV + Visible, 1.2 MLH 8.5% Yes Complies

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Updated stress time windows and annexure structure Annual SOP review and harmonization
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: Elixir Department: SOP for Use of Volumetric Filling Machine – V 2.0
Next Post: Sterile Injectable Manufacturing: SOP for Monitoring Room Conditions during Packaging – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version